1 Result

People

  1. Ilson
    Ilson
  2. Janjigian
    Janjigian
  3. Jones
    Jones
  4. Joshi
    Joshi
  5. Ku
    Ku
  6. Li
    Li
  7. Maron
    Maron
  8. Molena
    Molena
  9. Park
    Park
  10. Shcherba
    Shcherba

Groups

  1. Department of Medicine (1)
  2. Department of Pathology and Laboratory Medicine (1)
  3. Gastrointestinal Oncology Service (1)
  4. Hematologic Malignancies, Division of (1)
  5. Molecular Imaging and Therapy Service (1)
  6. Radiation Oncology, Department of (1)
  7. Radiology, Department of (1)
  8. Solid Tumor Oncology Division (1)
  9. Surgery (1)
  10. Survivorship Research (1)
  1. "261-376-453"
Formats
  1. Meeting Abstract (1)
Groups
  1. Department of Medicine (1)
  2. Department of Pathology and Laboratory Medicine (1)
  3. Gastrointestinal Oncology Service (1)
  4. Hematologic Malignancies, Division of (1)
  5. Molecular Imaging and Therapy Service (1)
  6. Radiation Oncology, Department of (1)

More Groups

People
  1. Abraham Wu (1)
  2. Bernard Park (1)
  3. Daniela Molena (1)
  4. David Ilson (1)
  5. David Jones (1)
  6. Geoffrey Ku (1)

More People

Years
  1. 2024 (1)
Publications
  1. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Clinical Oncology (1)

Results (1)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Wu, A. J. C.; Trivedi, N.; Maron, S. B.; Joshi, S. S.; Ilson, D. H.; Janjigian, Y. Y.; Shcherba, M.; Li, J.; Tang, L. H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save